Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 7/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.61 |
| ▸ | USP2 | O75604 | 6/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.61 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.61 |
| ▸ | ACP1 | P24666 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 7/20 | 0.60 |
| ▸ | TSHR | P16473 | 5/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 6/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | HBB | P68871 | 1/20 | 0.57 |
| ▸ | TLR9 | Q9NR96 | 3/20 | 0.56 |
| ▸ | MC4R | P32245 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1085578 | 0.87 | CYP1A2 (0.79) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL1085859 | 0.84 | ACP1 (0.71) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL1085597 | 0.81 | ACP1 (0.87) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL13312485 | 0.79 | ACP1 (0.70) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL1084058 | 0.78 | CYP1A2 (0.65) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL1085510 | 0.77 | ACP1 (0.70) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL3460634 | 0.76 | CYP1A2 (0.79) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL14233404 | 0.75 | TLR9 (0.71) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL13312480 | 0.74 | TLR9 (0.84) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 | |
| SCHEMBL14095304 | 0.73 | CYP1A2 (1.00) | CYP1A2CYP3A4USP2CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-09-28 | — | — | US | claimed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-20100160316-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-24 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2006-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160316-A1 | QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS | KCNN3, KCNN2, CACNA1I | CYP1A2 2515/4885CYP3A4 2226/4885USP2 3907/4885 |
| US-20060217377-A1 | Quinazolines useful as modulators of ion channels | KCNN3, KCNN2, CACNA1I | CYP1A2 2515/4885CYP3A4 2226/4885USP2 3907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.